tirucallane: from Simarouba amara (Simaroubaceae); structure in first source
tirucallane : A triterpene that is (13alpha,14beta,17alpha,20S)-lanostane.
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Simarouba amara | species | [no description available] | Simaroubaceae | A plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida. Leaves are alternate and compound. Most have small flowers, bitter bark, and fleshy fruits that are sometimes winged. Members contain QUASSINS.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 12312922 |
CHEBI ID | 73301 |
MeSH ID | M0503396 |
Synonym |
---|
tirucallane |
CHEBI:73301 |
(13alpha,14beta,17alpha,20s)-lanostane |
Q27140423 |
unii-cwp59nf9tf |
lanostane, (13alpha,14beta,17alpha,20s)- |
2151853-72-2 |
cwp59nf9tf , |
(5s,8r,9s,10r,13s,14r,17s)-4,4,10,13,14-pentamethyl-17-((2s)-6-methylheptan-2-yl)-2,3,5,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta(a)phenanthrene |
DTXSID501310798 |
lanostane, (13.alpha.,14.beta.,17.alpha.,20s)- |
(13.alpha.,14.beta.,17.alpha.,20s)-lanostane |
(5s,8r,9s,10r,13s,14r,17s)-4,4,10,13,14-pentamethyl-17-[(2s)-6-methylheptan-2-yl]-2,3,5,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene |
Class | Description |
---|---|
triterpene | A C30 terpene. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (7.14) | 29.6817 |
2010's | 42 (75.00) | 24.3611 |
2020's | 10 (17.86) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.61) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 56 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |